BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER

被引：0
|
作者：
Giammarco, S. [1 ]
Chiusolo, P. [2 ]
Metafuni, E. [1 ]
Sora, F. [2 ]
Laurenti, L. [2 ]
Innocenti, I. [1 ]
Autore, F. [1 ]
Bacigalupo, A. [2 ]
Sica, S. [2 ]
机构：
[1] IRCCS, Fdn Policlin Univ A Gemelli, Rome, Italy
[2] Univ Cattolica Sacro Cuore, IRCCS, Milan, Italy
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PU12
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [21] Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
    Paul, Shilpa
    Rausch, Caitlin R.
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03) : 166 - 175
  • [22] Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Stein, Anthony
    Franklin, Janet L.
    Chia, Victoria M.
    Arrindell, Deborah
    Kormany, William
    Wright, Jacqueline
    Parson, Mandy
    Amouzadeh, Hamid R.
    Choudhry, Jessica
    Joseph, Guiandre
    DRUG SAFETY, 2019, 42 (05) : 587 - 601
  • [23] Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
    Verneris, Michael R.
    Ma, Qiufei
    Zhang, Jie
    Keating, Amy
    Tiwari, Ranjan
    Li, Junlong
    Yang, Hongbo
    Agarwal, Abhijit
    Pacaud, Lida
    BLOOD ADVANCES, 2021, 5 (23) : 5387 - 5395
  • [24] Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Lia Gore
    Franco Locatelli
    Gerhard Zugmaier
    Rupert Handgretinger
    Maureen M. O’Brien
    Peter Bader
    Deepa Bhojwani
    Paul-Gerhardt Schlegel
    Catherine A. Tuglus
    Arend von Stackelberg
    Blood Cancer Journal, 8
  • [25] Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Gore, Lia
    Locatelli, Franco
    Zugmaier, Gerhard
    Handgretinger, Rupert
    O'Brien, Maureen M.
    Bader, Peter
    Bhojwani, Deepa
    Schlegel, Paul-Gerhardt
    Tuglus, Catherine A.
    von Stackelberg, Arend
    BLOOD CANCER JOURNAL, 2018, 8
  • [26] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    M S Topp
    M Stelljes
    G Zugmaier
    P Barnette
    L T Heffner
    T Trippett
    J Duell
    R C Bargou
    C Holland
    J E Benjamin
    M Klinger
    M R Litzow
    Leukemia, 2018, 32 : 562 - 565
  • [27] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Topp, M. S.
    Stelljes, M.
    Zugmaier, G.
    Barnette, P.
    Heffner, L. T., Jr.
    Trippett, T.
    Duell, J.
    Bargou, R. C.
    Holland, C.
    Benjamin, J. E.
    Klinger, M.
    Litzow, M. R.
    LEUKEMIA, 2018, 32 (02) : 562 - 565
  • [28] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
    Schub, A.
    Naegele, V
    Zugmaier, G.
    Brandl, C.
    Hijazi, Y.
    Topp, M. S.
    Kufer, P.
    Wolf, A.
    Klinger, M.
    ONKOLOGIE, 2013, 36 : 183 - 183
  • [29] Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Rambaldi, Alessandro
    Huguet, Francoise
    Zak, Pavel
    Cannell, Paul
    Tran, Qui
    Franklin, Janet
    Topp, Max S.
    BLOOD ADVANCES, 2020, 4 (07) : 1518 - 1525
  • [30] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
    Schub, Andrea
    Naegele, Virginie
    Zugmaier, Gerhard
    Brandl, Christian
    Hijazi, Youssef
    Topp, Max S.
    Kufer, Peter
    Wolf, Andreas
    Klinger, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345